Table 1 Baseline characteristics

All patients

653

100

Age at inclusion

  ≥ 55 years

271

41.5

  < 55 years

382

58.5

T status

 pT1

377

57.8

 pT2

234

35.8

 pT3-4

26

4.0

 pTX

16

2.5

N status

 pN0

419

64.2

 pN1

136

20.8

 pN2

59

9.0

 pN3

23

3.5

 pNX

16

2.5

Histological grade

 I

153

23.4

 II

322

49.3

 III

177

27.1

 Missing

1

0.2

HR status

 Positive (≥ 10%)

512

78.4

 Negative (0 to < 10%)

137

21.0

 Missing

4

0.6

HER2 status

 Negative

578

88.5

 Positive

71

10.9

 Missing

4

0.6

HR/HER2 subclasses

 HR+/HER2−

476

72.9

 HR+/HER2+

36

5.5

 HR−/HER2+

35

5.4

 HR−/HER2−

102

15.6

 Missing

4

0.6

Ki-67 (n = 218)^a

  < 15%

103

47.2

 15–30%

77

35.3

  ≥ 30%

38

17.4

Histological subtype

 Ductal

499

76.4

 Lobular

121

18.5

 Other

33

5.1

Adjuvant treatment

 No adjuvant

331

50.7

 Tamoxifen only

164

25.1

 CMF with or without Tam

158

24.2